These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2722864)

  • 1. A novel amino acid substitution in the reactive site of a congenital variant antithrombin. Antithrombin pescara, ARG393 to pro, caused by a CGT to CCT mutation.
    Lane DA; Erdjument H; Thompson E; Panico M; Di Marzo V; Morris HR; Leone G; De Stefano V; Thein SL
    J Biol Chem; 1989 Jun; 264(17):10200-4. PubMed ID: 2722864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombin Chicago, amino acid substitution of arginine 393 to histidine.
    Erdjument H; Lane DA; Panico M; Di Marzo V; Morris HR; Bauer K; Rosenberg RD
    Thromb Res; 1989 Jun; 54(6):613-9. PubMed ID: 2781509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single amino acid substitutions in the reactive site of antithrombin leading to thrombosis. Congenital substitution of arginine 393 to cysteine in antithrombin Northwick Park and to histidine in antithrombin Glasgow.
    Erdjument H; Lane DA; Panico M; Di Marzo V; Morris HR
    J Biol Chem; 1988 Apr; 263(12):5589-93. PubMed ID: 3162733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombin Sheffield: amino acid substitution at the reactive site (Arg393 to His) causing thrombosis.
    Lane DA; Erdjument H; Flynn A; Di Marzo V; Panico M; Morris HR; Greaves M; Dolan G; Preston FE
    Br J Haematol; 1989 Jan; 71(1):91-6. PubMed ID: 2917133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrate.
    Caso R; Lane DA; Thompson EA; Olds RJ; Thein SL; Panico M; Blench I; Morris HR; Freyssinet JM; Aiach M
    Br J Haematol; 1991 Jan; 77(1):87-92. PubMed ID: 1998601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin Milano, single amino acid substitution at the reactive site, Arg393 to Cys.
    Erdjument H; Lane DA; Ireland H; Di Marzo V; Panico M; Morris HR; Tripodi A; Mannucci PM
    Thromb Haemost; 1988 Dec; 60(3):471-5. PubMed ID: 3238650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin.
    Ireland H; Lane DA; Thompson E; Walker ID; Blench I; Morris HR; Freyssinet JM; Grunebaum L; Olds R; Thein SL
    Br J Haematol; 1991 Sep; 79(1):70-4. PubMed ID: 1911389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser.
    Borg JY; Owen MC; Soria C; Soria J; Caen J; Carrell RW
    J Clin Invest; 1988 Apr; 81(4):1292-6. PubMed ID: 3350974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis.
    Raja SM; Chhablani N; Swanson R; Thompson E; Laffan M; Lane DA; Olson ST
    J Biol Chem; 2003 Apr; 278(16):13688-95. PubMed ID: 12591924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombin-TRI (Ala382 to Thr) causing severe thromboembolic tendency undergoes the S-to-R transition and is associated with a plasma-inactive high-molecular-weight complex of aggregated antithrombin.
    Lindo VS; Kakkar VV; Learmonth M; Melissari E; Zappacosta F; Panico M; Morris HR
    Br J Haematol; 1995 Mar; 89(3):589-601. PubMed ID: 7734359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa.
    Austin RC; Rachubinski RA; Ofosu FA; Blajchman MA
    Blood; 1991 May; 77(10):2185-9. PubMed ID: 2029579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin.
    Okajima K; Abe H; Wagatsuma M; Okabe H; Takatsuki K
    Am J Hematol; 1995 Jan; 48(1):12-8. PubMed ID: 7832187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antithrombin P1 residue is important for target proteinase specificity but not for heparin activation of the serpin. Characterization of P1 antithrombin variants with altered proteinase specificity but normal heparin activation.
    Chuang YJ; Swanson R; Raja SM; Bock SC; Olson ST
    Biochemistry; 2001 Jun; 40(22):6670-9. PubMed ID: 11380262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombin and its deficiency states.
    Lane DA; Olds RR; Thein SL
    Blood Coagul Fibrinolysis; 1992 Jun; 3(3):315-41. PubMed ID: 1643210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleiotropic effects of antithrombin strand 1C substitution mutations.
    Lane DA; Olds RJ; Conard J; Boisclair M; Bock SC; Hultin M; Abildgaard U; Ireland H; Thompson E; Sas G
    J Clin Invest; 1992 Dec; 90(6):2422-33. PubMed ID: 1469094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombin Rouen-IV 24 Arg----Cys. The amino-terminal contribution to heparin binding.
    Borg JY; Brennan SO; Carrell RW; George P; Perry DJ; Shaw J
    FEBS Lett; 1990 Jun; 266(1-2):163-6. PubMed ID: 2365065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis.
    Okajima K; Abe H; Maeda S; Motomura M; Tsujihata M; Nagataki S; Okabe H; Takatsuki K
    Blood; 1993 Mar; 81(5):1300-5. PubMed ID: 8443391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site.
    Bock SC; Marrinan JA; Radziejewska E
    Biochemistry; 1988 Aug; 27(16):6171-8. PubMed ID: 3191114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombin and its inherited deficiencies.
    Perry DJ
    Blood Rev; 1994 Mar; 8(1):37-55. PubMed ID: 8205009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity.
    Devraj-Kizuk R; Chui DH; Prochownik EV; Carter CJ; Ofosu FA; Blajchman MA
    Blood; 1988 Nov; 72(5):1518-23. PubMed ID: 3179438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.